PCI Biotech is a cancer focused biopharmaceutical company headquartered in Norway and listed on the Oslo Stock Exchange. The company is developing therapeutic products based on its proprietary photochemical internalization (PCI) technology. The PCI technology induces triggered endosomal release and may be used to unlock the true therapeutic potential of a wide array of modalities, such as small molecules, ADCs and siRNA. Two programs are currently in clinical development in patient populations with a high unmet medical need; recurrent head & neck cancer (phase II) and bile duct cancer (phase I/II).
The PCI technology can also be used as an adjuvant platform for therapeutic and prophylactic vaccination. It has been demonstrated both in vivo and ex vivo that PCI may significantly increase the number of activated antigen-specific Killer T-cells by enhancing the MHC I antigen presentation of antigen presenting cells.
Please contact us, for more information.
PCI Biotech is a member of Oslo Cancer Cluster NCE. Oslo Cancer Cluster is a member organization for Norwegian and International stakeholders within cancer research and development. Oslo Cancer Cluster has members from the biotechnology industry, the government, patient organizations, research institutions and hospitals. Oslo Cancer Cluster aims to develop new cancer medication faster than today. Read more about Oslo Cancer Cluster here: www.oslocancercluster.no.